Diabetic retinopathy (DR) is a sight-threatening complication of diabetes and the main cause of blindness in the United States among working adults. Initially, DR progresses as a non-proliferative DR (NPDR) which leads to blinding proliferative DR (PDR). Nearly all people with Type 1 Diabetes (T1D) undergo gradual vision loss over a 20-year period of diabetes, and about 2030% of them progress to the advanced blinding stage of the disease, PDR.
Tight glycaemic management lowers the risk of complications, yet, many diabetic patients develop DR, despite having good glycaemic control. Furthermore, there is no cure or a preventive measure to block PDR. Only recently, over the past decade, with the advent of medicines that block the actions of the vascular endothelial growth factor (VEGF), has considerable progress been made in therapeutic options for PDR.
Nevertheless, not all patients achieve a satisfactory response and many of responders experience frequent invasive intravitreal injections and off-target effects, including increased risk of neuronal toxicity and geographic atrophy. While additional molecular targets, including the plasma kallikrein pathway, lipoprotein-associated phospholipase A2 (Lp-PLA2) and Tie-2, have been identified, with some being clinically evaluated, a critical gap still remains ineffective treatments.
Evidence suggests that targeting DR in the earlier stages, such as mild to moderate NPDR, before permanent damage occurs, would provide long-term benefit. In recent years, our research has focused on the molecular mechanisms of early DR including retinal oxidative stress, mitochondrial dysfunction, mitophagy, inflammation, and premature cell death in diabetes using both in vitro retinal cell cultures and in vivo diabetic rodent models.
Intriguingly, we have discovered a protein called thioredoxin-interacting protein (TXNIP) is strongly induced by diabetes in early DR where it is responsible for mediating cellular oxidative stress, mitophagy, inflammation and premature cell death. Knockdown of TXNIP by intravitreal injection of TXNIP shRNA prevents early molecular defects seen in DR. TXNIP binds to and inhibits the anti-oxidant and thiol-reducing capacity of thioredoxins (Trx) causing cellular redox imbalance and oxidative stress. Trx1 is present in the cytosol and nucleus while Trx2 is located in the mitochondrion. TXNIP is observed in all cellular compartments. Therefore, targeting TXNIP itself or downstream pathways could prevent or slow down the progression of early DR (NPDR) and hence PDR.
Currently, no clinically used, professional TXNIP inhibitors exist; however, several FDA-approved medicines have been reported to interfere with TXNIP pathway, but none of them has been used to treat DR. These drugs include amlexanox, tranilast, and romidepsin and they have been extensively studied for their efficacy, toxicity and safety. This consequently leads to saving time and money and may accelerate their entry to experimental clinical trials centred on targeting an over-activated TXNIP system to arrest DR away from their initial use.
Amlexanox is an inhibitor of TANK-Binding Kinase 1 (TBK1), which phosphorylates mitophagy adaptor optineurin and regulates mitophagic flux to lysosomes. In addition, TBK1 also phosphorylates interferon responsive factor 3 (IRF3) and mediates Type 1 interferon expression and inflammation. Tranilast has been shown to inhibit TXNIP and Nod-like NLRP3 inflammasome; therefore, it may help in preventing cellular oxidative stress and innate immune responses.
Therefore, a combination therapy using amlexanox and tranilast may prove to be effective in preventing or slowing down the progression of DR. Recently, we also demonstrated that a combination therapy of SS-31 (a mitochondria-targeted anti-oxidant), amlexanox and tranilast prevents auranofin-induced redox stress, mitochondrial-lysosomal axis dysregulation and proinflammatory pyroptotic cell death in retinal pigment epithelial cells, suggesting that combination therapies may be more effective than a single drug therapy.
In addition to drug treatment, gene therapy using a TXNIP promoter linked with a neuroprotective factor or an anti-oxidant gene may also be a potential approach for DR treatment. This is because the TXNIP promoter is strongly induced by hyperglycaemia in retinal cells in culture and in diabetic rodent retinas, but not under physiological glucose levels. In addition, the TXNIP promoter is also activated significantly by histone deacetylase inhibitors (HDACi), including suberoylanilide hydroxamic acid (SAHA) or romidepsin.
Therefore, HDACi and TXNIP-promoter gene therapy may also be incorporated in DR therapy for retinal neuroprotective gene expression, which could include pigment epithelium-derived factor (PEDF), glia-derived neurotrophic factor (GDNF), thioredoxin encoded Rod-Derived Cone Viability Factor (RdCVF) and others. These factors are known to be downregulated in DR.
It is currently accepted that neurodegeneration (particularly photoreceptor dysfunction) occurs early in DR before microvascular pathology develops. Therefore, early neuroprotective efforts may constitute a meaningful therapeutical approach to prevent or slow down the progression of late microvascular complications and PDR. Diabetes is a chronic and complex metabolic disease in which PDR develops only after prolonged hyperglycaemic exposure.
Therefore, a window of diabetic duration may exist early to prevent retinal neurovascular dysfunction and progression of PDR; within this time frame, we may devise preventive interventions activating endogenous genes or factors with neuroprotective drugs (preferably orally active drugs) and gene therapy including those mentioned above.
Such a hypothesis is supported by a recent observation, which showed that the expression of retinol binding protein 3 (RBP3), a protein secreted by photoreceptors in the retina, may play a protective role against PDR. RBP3 interacts with glucose transporter Glut1 and reduces excess cellular glucose uptake under hyperglycaemia in diabetics, thus, preventing glucotoxicity in retinal cells including Muller glia and capillary endothelial cells. Those individuals expressing RBP3 do not develop PDR although they have had 50 years of T1D.
In conclusion, new preventive therapies for PDR may be successfully developed by activating endogenous cellular survival mechanisms using drug and gene therapies once a clinical sign of NPDR is observed but before PDR. Such treatments may prevent blindness in diabetic patients.
References
1 Perrone L, Devi TS, Hosoya KI, Terasaki T, Singh LP. Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy. Cell Death Dis. 2010 Aug 19;1:e65. PMID: 21364670.
2 Devi TS, Somayajulu M, Kowluru RA, Singh LP. TXNIP regulates mitophagy in retinal Mller cells under high-glucose conditions: implications for diabetic retinopathy. Cell Death Dis. 2017 May 11;8(5):e2777. PMID: 28492550.
3 Lalit PS, Thangal Y, Fayi Y, Takhellambam SD. Potentials of Gene Therapy for Diabetic Retinopathy: The Use of Nucleic Acid Constructs Containing a TXNIP Promoter. Open Access J Ophthalmol. 2018;3(2). PMID: 31106306.
4 Devi TS, Yumnamcha T, Yao F, Somayajulu M, Kowluru RA, Singh LP. TXNIP mediates high glucose-induced mitophagic flux and lysosome enlargement in human retinal pigment epithelial cells. Biol Open. 2019 Apr 25;8(4). PMID: 31023645.
5 Yumnamcha T, Devi TS, Singh LP. Auranofin Mediates Mitochondrial Dysregulation and Inflammatory Cell Death in Human Retinal Pigment Epithelial Cells: Implications of Retinal Neurodegenerative Diseases. Front Neurosci. 2019 Oct 10;13:1065. PMID: 31649499.
6 Yokomizo H, Maeda Y, Park K, Clermont AC, Hernandez SL, et. al., Retinol binding protein 3 is increased in the retina of patients with diabetes resistant to diabetic retinopathy. Sci Transl Med. 2019 Jul 3;11(499). PMID: 31270273.
7 Ibrahim AS, Saleh H, El-Shafey M, Hussein KA, et. al., Targeting of 12/15-Lipoxygenase in retinal endothelial cells, but not in monocytes/macrophages, attenuates high glucose-induced retinal leukostasis. BBA: Mol Cell Biol Lipids. 2017 Jun;1862(6):636-645. PMID: 28351645.
8 Ibrahim AS, Elshafey S, Sellak H, Hussein KA, El-Sherbiny M, et. al., A lipidomic screen of hyperglycemia-treated HRECs links 12/15-Lipoxygenase to microvascular dysfunction during diabetic retinopathy via NADPH oxidase. J Lipid Res. 2015 Mar;56(3):599-611. PMID: 25598081.
Funding
NIH/NEI R01 EY023992 (LSP, OVAS).
NIH/NEI core grant P30EY004068 (LDH, OVAS).
Research to Prevent Blindness (MSJ, OVAS).
American Heart Association Grant 18CDA34080403 to ASI.
Please note: This is a commercial profile
Editor's Recommended Articles
Continued here:
Repurposing FDA-approved medicines and gene therapy to combat diabetic retinopathy - Open Access Government
- The Longevity Wake-Up Call And The Blindness Of Leadership To It - Forbes - February 24th, 2025
- Album Review: Blindness // The Murder Capital - The Indiependent - February 24th, 2025
- The Murder Capital - Blindness - Northern Transmissions - February 24th, 2025
- The Murder Capital: Blindness review - independent pop | Indie - The Line of Best Fit - February 24th, 2025
- Prevent Blindness Kicks Off Second Annual "Retinopathy of Prematurity (ROP) Awareness Week," Feb. 24- March 2, 2025, as Part of its ROP... - February 24th, 2025
- Prevent Blindness Kicks Off Second Annual Retinopathy of Prematurity Awareness Week - Vision Monday - February 24th, 2025
- Gene therapy for rare childhood blindness shows lasting vision gains - R&D World - February 24th, 2025
- The Murder Capital's Blindness: A Voice of Significance in an Era Craving Authentic Discourse - Indie Is Not A Genre - February 24th, 2025
- Albums Of The Week: The Murder Capital | Blindness - Tinnitist - February 24th, 2025
- After Maine native testifies before Congress, Elon Musk targets his disability - Press Herald - February 24th, 2025
- Ozempic could BLIND you - it damages veins in the eye, major study finds - Daily Mail - February 24th, 2025
- Cerebral Venous Thrombosis Presenting With Binocular Blindness and Bilateral Sensorineural Hearing Loss - Cureus - February 24th, 2025
- Treatment for horses may lead to therapy for type of blindness - Mid Florida Newspapers - February 24th, 2025
- The Murder Capital: Blindness album review - Louder Than War - February 24th, 2025
- 'First in the world': London doctors cure blindness in children born with a genetic condition - WION - February 24th, 2025
- Doctors cure rare blindness in infants with gene therapy - NewsBytes - February 24th, 2025
- Gene therapy new trial treats rare blindness in children - Daily Jang - February 24th, 2025
- Ozempic Blindness Could Be Rare but Real: What Experts Say About the Risk - ZME Science - February 24th, 2025
- Parents of boy with rare eye condition hail amazing results of gene therapy - Yahoo News UK - February 24th, 2025
- Myths and Assumptions about Blindness - BBC.com - February 24th, 2025
- Man accused of beating victim, causing permanent blindness in one eye - KAIT - February 15th, 2025
- Scientists Find Link Between Weight Loss Drugs and Blindness - AOL - February 15th, 2025
- Treatment for horses may lead to therapy for type of blindness - University of Florida - February 15th, 2025
- How Ageism Impacts Adults with Low Vision - National Council on Aging - February 15th, 2025
- Ozempic and other weight loss drugs may be linked to conditions that could lead to blindness, study says - Quartz - February 15th, 2025
- Treatment for horses may lead to therapy for type of blindness - Phys.org - February 15th, 2025
- Treatment for Horses May Lead to Therapy for Type of Blindness - Morning Ag Clips - - February 15th, 2025
- Foundation Fighting Blindness Celebrates 20 Years of VisionWalk - PR Newswire - February 15th, 2025
- Woman Victim of 'Lash Blindness'Shock at How She Looks Without Them - Newsweek - February 15th, 2025
- Some Ozempic users are losing their vision - but scientists dont know why - The Independent - February 15th, 2025
- Those with visual impairments or blindness tackling the trails at Pico Mountain - WCAX - February 15th, 2025
- Prevent Blindness Issues Call for Nominations for the 2025 Jenny Pomeroy Award for Excellence in Vision and Public Health, and Rising Visionary Award... - February 15th, 2025
- Medical warning: Ozempic and Mounjaro may be linked to vision loss - India Today - February 15th, 2025
- New research links Ozempic to vision loss and risk of blindness - MSN - February 15th, 2025
- Ozempic Blindness: Weight Loss Drugs Linked to This Condition, Experts Warn - Tech Times - February 15th, 2025
- Ozempic Blindness Lawsuit Mounts: Shocking Side Effect Of Weight Loss Drug Is 'Eye Stroke,' What You Need To Know - IBTimes UK - February 15th, 2025
- The Politics Of Erasure: Gaza, Genocide, And The Wests Wilful Blindness OpEd - Eurasia Review - February 15th, 2025
- WHO launches new initiative to tackle the main cause of vision impairment - December 19th, 2024
- Blindness Advocates on Why There Should Be Audio Description Oscars - Variety - December 19th, 2024
- Diabetic retinopathy is treatable and preventable but only if you catch it in time - USA TODAY - December 19th, 2024
- AI: Could it help prevent blindness in diabetics? - BBC.com - December 19th, 2024
- Health Officials Investigate Rare Form of Blindness Tied to Ozempic - Gizmodo - December 19th, 2024
- Ozempic Could Be Blinding People Trying to Lose Weight - VICE - December 19th, 2024
- What is retinitis pigmentosathe vision disorder in the movie Blink? - National Geographic - December 19th, 2024
- VR shows promise in aiding navigation of people with blindness or low vision - Health Tech World - December 19th, 2024
- Ozempic could be linked to a common cause of sudden blindness, study finds - Quartz - December 19th, 2024
- New virtual realitytested system shows promise in aiding navigation of people with blindness or low vision - Tech Xplore - December 19th, 2024
- Ex-meth user who gouged her own eyeballs out while high says she is happier years after nightmarish episode - New York Post - December 19th, 2024
- Officials investigating link between Ozempic and eye-rotting disease that makes people blind - Daily Mail - December 19th, 2024
- Youngster to 'have eye removed' after minor fall - but NHS waitlist 'over 3 years' - NationalWorld - December 19th, 2024
- Restoring Vision: The Promise of Stem Cells in Healing Blindness - This is Local London - December 19th, 2024
- COAVS and Fred Hollows Foundation strengthen efforts to combat blindness in Pakistan - 24newshd - December 19th, 2024
- Study finds link between Ozempic and increased risk of vision loss - The Express Tribune - December 19th, 2024
- Going blind at 33 is devastating I wont see my childrens faces as they grow up - The Telegraph - December 19th, 2024
- Europol terror report reveals stark blindness about where the danger lies - Gript - December 19th, 2024
- Elton John lost his vision; signs and symptoms of eye infections that can cause blindness - The Times of India - December 6th, 2024
- Elton John's battle with blindness: How 77-year-old star's husband David Furnish guided him around premiere as - Daily Mail - December 6th, 2024
- Experimental study shows connection between COVID infection and age-related blindness - Medical Xpress - December 6th, 2024
- Elton John confirms shocking blindness after severe infection fight: I havent been able to see.. - Hindustan Times - December 6th, 2024
- Yes, an Eye Infection *Can* Lead To Vision Loss Heres How - Katie Couric Media - December 6th, 2024
- Elton John Battling Partial Blindness After Serious Eye Infection - Digital Music News - December 6th, 2024
- CU Anschutz researchers working to cure blindness through total eye transplantation - 9News.com KUSA - December 6th, 2024
- Elton John lost his vision from an eye infection. Here's why that might happenand how to prevent it - Fortune - December 6th, 2024
- Elton John announces blindness due to infection - CBS19.tv KYTX - December 6th, 2024
- David Frost: I suffer from face blindness. As a politician, being unable to identify people is agony - The Telegraph - December 6th, 2024
- Hes still standing how Elton John has survived far worse than blindness - The Telegraph - December 6th, 2024
- Foundation Fighting Blindness Partners with University of Colorado Anschutz Medical Campus and Other Leading Institutions to Secure Up to $46 Million... - December 6th, 2024
- Walmart helping low vison and blind customers shop with new app - KSLA - December 6th, 2024
- Elton John Says He Is Blind In The Right Eye Due to An Infection; What Is It All About? - Times Now - December 6th, 2024
- Trumps Win: The Blindness of Republicans and Democrats - The Times of Israel - December 6th, 2024
- Heres every song on The Agency soundtrack - NME - December 6th, 2024
- Elton John's worrying health battles in full as he confirms blindness - The Mirror - December 6th, 2024
- Symptoms of serious eye infections after Elton John says he is now blind - LADbible - December 6th, 2024
- Shocking! Elton John Reveals Blindness After Severe Eye Infection: Havent Been Able To... - Republic World - December 6th, 2024
- Face blindness will be examined as part of new project - BBC - December 6th, 2024
- Make your Word documents accessible to people with disabilities - November 27th, 2024
- Make your Word documents accessible to everyone with Accessibility ... - November 27th, 2024
- Use color and contrast for accessibility in Microsoft 365 - Microsoft ... - November 27th, 2024
- Accessibility tools for Word - Microsoft Support - November 27th, 2024
- Rules for the Accessibility Checker - Microsoft Support - November 27th, 2024